📰 Double Blind Phase News
Double Blind Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Double Blind Phase. Real-time updates on events, politics, business and more.
January 30, 2024
Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
January 26, 2024
Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
October 30, 2023
Highlights: Participant screening closed for ATH434-201 Phase 2 studyIndependent Data Monitoring Committee recommended the ATH434-201 Phase 2 study continue as plannedReceived A$4.74M cash refund...
August 11, 2023
BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...
April 3, 2023
STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB and its partner Eisai has presented new findings on lecanemab , an anti-amyloid beta protofibril antibody for the treatment of Alzheimers... | April 3, 2023
April 3, 2023
STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI)
April 3, 2023
STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner...
March 31, 2023
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
March 31, 2023
FinancialContent fully hosted finance channel
March 31, 2023
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts